Get Pharma & Biotech every Monday

One free email with what the biggest companies in Pharma & Biotech filed, were granted and gave up this week.

Vol. 1A weekly digest of the patent recordEvery Monday

The Thicket. Pharma & Biotech patents this week.

Pharma & BiotechPfizer, Moderna, Eli Lilly, Merck & Co., Bristol Myers Squibb, AstraZenecaGet it every Monday →

Issue 001 / Week of Nov 16, 2026

19FILED9GRANTED

Bristol-Myers Squibb secures patents on TREM-1 and Vista antibodies.

Also: Pfizer granted a patent for solid forms of pyrazolo[3,4-d]pyrimidine compounds, and ModernaTX received grants for SARS-CoV-2 mRNA domain vaccines and lipid nanoparticle delivery to airway epithelium.

Fig. 001
Patent drawing from USPTO 20260355239A1, labelled glycoprotein (100)
Combination of a T Cell Therapy and Continuous or Intermittent Dgk…2026
Juno TherapeuticsUSPTO 20260355239A1 (opens in a new tab)
The ThicketVol. 1

Also this week

3

In brief.

Also this week
The ThicketVol. 1

Companies

4
ModernaGrant

ModernaTX granted patent for lipid nanoparticle delivery to airway epithelium.

On November 10, 2026, the USPTO granted US Patent 12,788,726 to ModernaTX for processes to prepare lipid nanoparticle compositions that deliver therapeutic or prophylactic agents to airway epithelium. The patent covers methods for formulating these nanoparticles to target the airway lining, as outlined in the granted document PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM.

Bristol-Myers SquibbPublication

Juno Therapeutics publishes application for T cell therapy combined with DGK inhibitor dosing.

Juno Therapeutics published an application on November 12, 2026, describing a combination therapy for cancer that pairs engineered T cells with a Diacylglycerol kinase (DGK) inhibitor. The company addresses the need for improved persistence and activity of T cells after administration by initiating the DGK inhibitor between Days 1 and 8 of treatment and continuing it until the engineered T cell count peaks. Several claims covering broader dosing ranges and specific chemical structures were cancelled during prosecution, while the remaining claims were amended to specify the timing of inhibitor initiation relative to the T cell infusion.

The ThicketVol. 1Subscribe→

Get Pharma & Biotech every Monday.

Big Law patents. In plain sight.

The all-in-one patent firm for startups. Former Big Law patent experts and PhDs, on AI that runs on our own GPUs.

Social

Newsletter

Stay updated on the future of intellectual property.

Fearn Legal, LLC is a patent prosecution firm, licensed to file and prosecute patents across the USPTO. The information provided here is for general informational purposes only and does not constitute legal advice. Viewing this information or contacting us through this website does not create an attorney-client or patent agent-client relationship. For personalized legal advice, please reach out to us directly to set up a legal consult or consult directly with a qualified attorney.

Big Law patents. In plain sight.

Social

Newsletter

Stay updated on the future of intellectual property.

Fearn Legal, LLC is a patent prosecution firm, licensed to file and prosecute patents across the USPTO. The information provided here is for general informational purposes only and does not constitute legal advice. Viewing this information or contacting us through this website does not create an attorney-client or patent agent-client relationship. For personalized legal advice, please reach out to us directly to set up a legal consult or consult directly with a qualified attorney.

Big Law patents. In plain sight.

The all-in-one patent firm for startups. Former Big Law patent experts and PhDs, on AI that runs on our own GPUs.

Social

Newsletter

Stay updated on the future of intellectual property.

Fearn Legal, LLC is a patent prosecution firm, licensed to file and prosecute patents across the USPTO. The information provided here is for general informational purposes only and does not constitute legal advice. Viewing this information or contacting us through this website does not create an attorney-client or patent agent-client relationship. For personalized legal advice, please reach out to us directly to set up a legal consult or consult directly with a qualified attorney.